Sysmex Grows by 12% and Reaches 3 Billion in 2023

Sysmex continues to grow. The Japanese healthcare technology group has closed the 2023 financial year with double-digit growth in all business lines. Specifically, the company grew by 12.4% worldwide, reaching 2.8 billion euros, according to Peter Georgi, general manager of Sysmex in Iberia.

The group, which arrived in Spain in 2008, has two business areas: routine diagnostics (which includes haematology and urine) and life science , specialising in oncology, with which it began operating in the Spanish market. The company highlights the good performance of its two areas, especially routine analysis, which grew by 30%, while life science increased its sales by 10% compared to the previous year.

Sysmex is embarking on a five-year growth plan in Spain, of which it has already completed three. Among the most significant events in this plan is the transfer of the distribution of its haematology products , an operation that until three years ago was carried out by Roche Diagnostics.

“Roche remains a very important partner for us, with whom we work together on tenders and projects,” said Georgi. The executive was appointed general manager last April, after having served as Business Unit Manager of Diagnostics in Iberia.

Sysmex expects to increase its revenues by 10% in Spain for the year 2024

Sysmex’s business expansion in Spain is also due to organic growth with new clients in Seville and Granada , reaching a 50% market share in the hematology area in Spain. In parallel, the company completed the installation of new systems in the province of Granada, with four large hospitals, in addition to having won an important tender in Seville and in Catalonia, where it managed to install its hematology services in all public hospitals in the community.

The company has also launched new products in the last year , which allow for faster diagnostics, such as the introduction of the XR series of hematology analyzers to the market. It also introduced its hemostasis line in Spain, diagnostic solutions that allow for the detection and analysis of coagulation disorders.

On the life science side, Sysmex continues to consolidate Osna, a device that allows the detection of lymph node metastases . In addition, since last April, the group has been distributing coagulation products directly to customers throughout the European Union (EU), a service previously offered by Siemens, also a partner of the Japanese company in the Old Continent. “This way we can offer a more complete service to our customers,” said Georgi.

The company also launched PA100, a small device that can diagnose urinary tract infections , one of the most common infections today. With this equipment, in fifteen minutes you can determine if there is an infection and in thirty minutes you can identify resistance. “In Spain and worldwide there is a lot of resistance to antibiotics and with this we can offer a great advance against this problem.”

Sysmex employs 160 workers throughout Spain

Sysmex, however, expects to continue growing at double digits in the Spanish market, albeit at a slower pace, with a 10% increase in its turnover for the next fiscal year. The company, which carries out around sixty million tests in Spain per year in the area of ​​routine diagnosis, also expects to reach 25,000 patients in the area of ​​life science in 2025.

Sysmex’s growth plans also extend to its workforce. Based in Sant Just Desvern (Barcelona), the company has grown from a team of 100 employees to more than 160 today , in the Spanish market alone.

The company has technical teams in all autonomous communities, supporting its clients with engineers or biologists. Sysmex has a logistics provider, UPS Healthcare. The reagents are produced in Germany, while the equipment comes mostly from Japan. The company also has a headquarters in Porto to control its business in Portugal.

Present in Spain since 2008, Sysmex has positioned itself among the leading companies in the life science sector. “Spain is a market that is very open to innovation and to appreciating advances, with highly competent and committed professionals,” Georgi confessed. “This environment conducive to innovation also benefits patients,” added the executive. On a global scale, Sysmex operates in more than 190 countries and provides a wide range of medical diagnostic products and solutions.

__

(Featured image by Lucas Vasquez via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us